SEC EDGARJul 9$IONS

BENNETT C FRANK sold $1.3M of IONS (indirect holdings)

BENNETT C FRANK (EVP, Chief Scientific Officer) sold 15,000 indirectly-held shares of IONIS PHARMACEUTICALS INC (IONS) at $85.46 ($1.28M total) on 2026-07-07 under a Rule 10b5-1 trading plan.

Original reporting

SEC EDGAR · BENNETT C FRANK

Published Jul 9, 2026, 11:26 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Jul 9, 2026, 11:29 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$IONS

Neutral

high confidence

Mentioned

$IONS

Relevance

5/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$IONSNeutralLow

Why it matters

The only new information is the size, price, and timing of the insider sale; it does not include any new clinical, regulatory, or financial datapoints.

Market read

Traders may monitor insider activity, but this specific disclosure is unlikely to drive a material repricing without additional company-specific catalysts.

What to watch

The transaction is explicitly pre-arranged and the holdings after the transaction are 0 shares, which can reflect diversification or scheduled liquidity needs rather than company outlook.

Relevance 5/10Novelty 3/10Timing: Filed July 9, covering a July 7 sale under a 10b5-1 plan.

Background

The article is a SEC Form 4 insider transaction disclosure for Ionis Pharmaceuticals.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$IONSNeutralHigh confidence

Context

Ionis Pharmaceuticals disclosed an EVP Chief Scientific Officer open-market sale of 15,000 shares at $85.4620 on a 10b5-1 plan.

Expected impact

Likely limited near-term impact; traders may view it as routine 10b5-1 selling rather than a signal.

Evidence & confidence

The filing is a Form 4 for an indirect holdings sale under a pre-arranged Rule 10b5-1 plan, with no accompanying operational or guidance change.

Market effects

Sector

No clear read-across to the biotech sector from a single routine insider sale.

Regional

None.

Global

None.

Counterpoint

What could challenge this read

Even with a 10b5-1 plan, some traders may interpret repeated insider selling as a mild bearish signal about near-term risk.

Key entities

issuer
IONIS PHARMACEUTICALS INC
Company whose insider transaction was reported on Form 4.
insider
BENNETT C FRANK
EVP, Chief Scientific Officer who sold shares under a Rule 10b5-1 plan.

Read at source ← All news

$IONSLowAI 9/10

Pelacarsen no better than placebo in patients with high lipoprotein(a), heart disease

Ionis and Novartis' pelacarsen failed to reduce major adverse CV events in patients with high lipoprotein(a) and heart disease, according to the Lp(a)HORIZON trial. The drug did not outperform placebo in reducing CV events, with similar rates in both groups. The trial included 8,322 patients, with a median follow-up of 4.7 years. Despite the setback, experts urge continued research into lipoprotein(a) treatments.

healio.comNov 7

$NVSMed

Novartis is said to be abandoning Ionis heart drug after late-stage trial setback

Novartis NVS is halting development of Ionis IONS's heart drug pelacarsen after it failed a late-stage trial. The therapy did not meet its primary endpoint in the Lp(a)HORIZON trial for cardiovascular disease. Novartis will continue testing pelacarsen for calcific aortic valve stenosis. Amgen AMGN, Arrowhead ARWR, and Royalty Pharma RPRX also saw shares drop in September due to the setback.

tradingview.comNov 7

$NVSHigh

Novartis abandoning Ionis heart drug post trial setback (NVS)

Novartis (NVS) will halt development of a heart disease drug discovered by Ionis (IONS) after it failed in a late-stage trial in September, according to Bloomberg.

seekingalpha.comNov 7

$GSKMed

Hibsago (bepirovirsen) approved in Canada as the first and only finite therapy indicated to achieve functional cure of chronic hepatitis B

GSK's Hibsago (bepirovirsen) approved in Canada for chronic hepatitis B, offering a finite treatment option. Approval based on Phase III trials showing 19-26% functional cure rates. Targets 262,000 Canadians with chronic hepatitis B, a leading cause of liver cancer. Supply expected in early 2027.

northernnews.caNov 3

$NVSMed

novartis heart drug lp(a) trial failure raises heart health questions

Novartis and Ionis' heart drug pelacarsen failed to reduce heart attack or stroke risk in a trial, despite cutting Lp(a) levels by 80%. The results challenge the belief that lowering Lp(a) benefits heart health, raising questions for doctors and investors.

shafaqna.comNov 3

$IONSMed

After 30 Years, FDA Approves First-Ever Drug For a Rare Neurological Disorder

The FDA has approved zilganersen (Zanvastro), the first drug to treat Alexander disease, a rare neurological disorder. Developed by Ionis Pharmaceuticals, the drug reduces GFAP production. Clinical trials showed stabilization or improvement in motor skills, with mild to moderate side effects. The drug is administered via spinal injection every three months.

sciencealert.comOct 29